Avoiding statin myopathy: understanding key drug interactions

Bibliography

• Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106, 1024–1028 (2002)
   Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C,Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc. Drugs Ther. 19, 403–414 (2005)
   Google Scholar
• Sacks FM. Adherence to statin therapy: why aren’t we doing better? Am. J. Med. 113, 685–686 (2002)
   Google Scholar
• Bouchard M-H, Dragomir A, Blais L, Berard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br. J. Clin. Pharmacol. 63, 698–708 (2007)
   Google Scholar
• Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92, K23–K29 (2003)
   Google Scholar
• Silva M, Matthews ML, Jarvis C et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 29, 253–260 (2007)
   Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Inten. Med. 150, 858–868 (2011)
   Google Scholar
• Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413–428 (1999)
   Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389–430 (1998)
   Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 11, 323–332 (2010)
   Google Scholar
• White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42, 963–970 (2002)
   Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 94(9), 1140–1146 (2004)
   Google Scholar
• Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. 46, 49–53 (1998)
   Google Scholar
• Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63, 332–341 (1998)
   Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64, 58–65 (1998)
   Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 64, 177–182 (1998)
   Google Scholar
• Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol. 39, 501–504 (1999)
   Google Scholar
• Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol. 42, 444–449 (2002)
   Google Scholar
• Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol.Ther. 64, 369–377 (1998)
   Google Scholar
• Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann. Pharmacother. 36, 1546–1549 (2002)
   Google Scholar
• Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann. Inten. Med. 140(8), W31 (2004)
   Google Scholar
• Group SC, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Eng. J. Med. 359, 789–799 (2008)
   Google Scholar
• Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. 93, 215–219 (1997)
   Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569–577 (2002)
   Google Scholar
• Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118–127 (1999)
   Google Scholar
• Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. 58, 56–60 (2004)
   Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63, 397–402 (1998)
   Google Scholar
• Rogers JD, Zhao J, Liu L et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66, 358–366 (1999)
   Google Scholar
• Hidaka M, Okumura M, Fujita K et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab. Dispos. 33, 644–648 (2005)
   Google Scholar
• Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am. J. Cardiol. 98, 705–706 (2011)
   Google Scholar
• Kantola T, Backman JT, Niemi M, KivistoKT, Neuvonen PJ. Effect of fluconazole onplasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56, 225–229 (2000)
   Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425–446 (2011)
   Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693–705 (2011)
   Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356–366 (2011)
   Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726–733 (2007)
   Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873–879 (2011)
   Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229–1236 (2011)
   Google Scholar
• Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793–1806 (2011)
   Google Scholar
• Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 5, 2236–2243 (2005)
   Google Scholar
• Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65, 410–413 (1993). 41 Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62, 311–321 (1997)
   Google Scholar
• Regazzi MB, Iacona I, Campana C et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25, 2732–2734 (1993)
   Google Scholar
• Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications fororgan transplant recipients. Drugs 63, 367–378 (2003)
   Google Scholar
• Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361(9374), 2024–2031 (2003)
   Google Scholar
• Matsushima S, Maeda K, Kondo C et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314, 1059–1067 (2005)
   Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5, 703–729 (2011)
   Google Scholar
• Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18, 401–408 (2007)
   Google Scholar
• Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Kim HS. Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability. Eur. J. Clin. Nutr. 65, 110–116 (2011)
   Google Scholar
• Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340–345 (2001)
   Google Scholar
• Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76, 13 (1995)
   Google Scholar
• Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51, 2375–2384 (2008)
   Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41(4 Suppl. 3), I–IV, S1–S91 (2003)
   Google Scholar
• Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. 8, 35–41 (2011)
   Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 41, 1195–1211 (2002)
   Google Scholar
• Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin.Endocrinol. Metab. 74, 1045–1052 (1992)
   Google Scholar
• Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect. Dis. 7, 787–796 (2007)
   Google Scholar
• Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokineticinteractions. J. Antimicrob. Chemother. 56, 1–5 (2005).
   Google Scholar
• Ray GM. Antiretroviral and statin drug–drug interactions. Cardiol. Rev. 17, 44–47 (2011)
   Google Scholar
• Huang S-M, Lesko L, Temple R. Adverse drug reactions and interactions. In: Pharmacology and Therapeutics: Principles to Practice. Waldman SA, Terzic A (Eds). Elsevier, PA, USA, 271 (2011)
   Google Scholar